描述了开发两个导致生产> 1000 kg BMS-663068(3)的可行途径的过程。为支持发展活动和最初的临床试验而确定的最初100千克递送的路线涉及将2-氨基-4-甲基吡啶转化为母体活性药物成分(API),然后进行前药安装和脱保护。为了消除二的父API和合成的问题的隔离吨丁基(氯甲基)酯,磷酸一第二代前药安装路线被开发其中涉及一个后期常用中间体的转化为N(1) -thioether衍生物随后氯甲基,位移二吨丁基磷酸钾,并脱保护。第二种策略导致API以14线性步长的多千克级规模制备API,总产率约为7%。
[EN] BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY<br/>[FR] CONJUGUÉS BIOACTIFS POUR L'ADMINISTRATION D'OLIGONUCLÉOTIDES
申请人:UNIV MASSACHUSETTS
公开号:WO2017030973A1
公开(公告)日:2017-02-23
Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
[EN] CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE<br/>[FR] AMPLIFICATEUR DE SENSIBILITÉ CHIMIOSÉLECTIF POUR MARQUER UN PEPTIDE, UN CONJUGUÉ PEPTIDIQUE OU UNE MOLÉCULE RÉACTIVE SIMILAIRE
申请人:INDIAN INSTITUTE OF SCIENCE EDUCATION AND RES BHOPAL
公开号:WO2020245843A1
公开(公告)日:2020-12-10
The invention pertains to chemoselective sensitivity booster for tagging a peptide, peptide conjugate, or similar reactive molecule for analysis of a peptide, protein, antibody, protein bioconjugate, antibody bioconjugate, and similar analytes. The sensitivity booster comprises of sp2 or sp3 nitrogen centers in combination with hydrophobic carbon chains linked with an electrophile or nucleophile for attachment with a peptide, peptide conjugate, or molecules with similar reactivity.
申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
公开号:US20160130205A1
公开(公告)日:2016-05-12
The present invention concerns a process for creating a Carbon-Carbon bond (C—C) or a Carbon-Heteroatom bond (C—HE) by reacting a compound carrying a leaving group with a nucleophilic compound carrying a carbon atom or a heteroatom (HE) that can substitute for the leaving group, creating a C—C or C—HE bond, wherein the reaction takes place in the presence of an effective quantity of a. a catalytic system comprising a ligand and at least a metal-based catalyst, such a metal catalyst being chosen among iron or copper compounds proviso that only a single metal is present.
[EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS BENZÈNESULFONAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
申请人:XENON PHARMACEUTICALS INC
公开号:WO2017201468A1
公开(公告)日:2017-11-23
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.
[EN] PROCESS FOR THE PREPARATION OF ORGANIC BROMIDES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BROMURES ORGANIQUES
申请人:TECHNION RES & DEV FOUNDATION
公开号:WO2017060905A1
公开(公告)日:2017-04-13
The present invention provides a process for the preparation of organic bromides, by a radical bromodecarboxylation of carboxylic acids with a bromoisocyanurate.